RxDoctor Payments Data

Roshni Kundranda, MD

Internal Medicine · Scottsdale, AZNPI 1700955838

Payments from drug & device makers

$2,854in general payments, 2019–2025

Across 18 payments — averaging $158.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$2K
  • Qiagen, LLC$192
  • Roche Diagnostics Corporation$123
  • AbbVie$41
  • Teva Pharmaceuticals USA, Inc.$34
  • AstraZeneca$28
  • plus $79 from 5 others

What the payments were for

  • Consulting fees$2,25679%
  • Food & beverage$59821%

General payments by program year

19
20
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,854 in reported general payments places this provider in the 85th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$118,614
Medicare patients
365
Services billed
1,530

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban69$92,862
OzempicSemaglutide40$59,609
JardianceEmpagliflozin17$28,861
ProliaDenosumab13$22,273
XareltoRivaroxaban14$19,500
JanuviaSitagliptin Phosphate13$18,270
TrulicityDulaglutide15$16,836
MyrbetriqMirabegron13$16,304
Advair HfaFluticasone Propion/Salmeterol17$9,989
Atorvastatin Calcium639$6,817
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$6,096
Fluticasone-SalmeterolFluticasone Propion/Salmeterol18$4,702
Levothyroxine Sodium384$4,429
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$4,370
Rosuvastatin Calcium223$3,999

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$13$59,60940 claims
MerckJanuvia$12$18,27013 claims
AbbVieSynthroid$41$90019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →